Clinical trials evaluating PD-1 inhibitors (e.g., pembrolizumab, nivolumab) and PD-L1 inhibitors (e.g., atezolizumab, durvalumab) in osteosarcoma patients have demonstrated mixed outcomes. This evidence concerns the gene PDCD1 and osteosarcoma.